Product InformationRegistration Status: Active
SAIZEN SOLUTION FOR INJECTION 8.00MG/ML (12MG IN 1.50ML) is approved to be sold in Singapore with effective from 2013-06-11. It is marketed by MERCK PTE LTD, with the registration number of SIN14425P.
This product contains Somatropin 12mg/ml in the form of INJECTION, SOLUTION. It is approved for SUBCUTANEOUS use.
This product is manufactured by Merck Serono S.p.A in ITALY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Recombinant human growth hormone (somatotropin) 191 residues, MW 22.1 kD, synthesized in E. coli
For treatment of dwarfism, acromegaly and prevention of HIV-induced weight loss
Mechanism of Action
hGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules, including MAP kinases, insulin receptor substrates, phosphatidylinositol 3' phosphate kinase, diacylglycerol, protein kinase C, intracellular calcium, and Stat transcription factors. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism.
* 2.3 +/- 1.8 mL/min/kg [GHD patients (IV 33 ng/kg/min)]
Growth hormone | Growth hormone (human) | hGH | Human growth hormone | Recombinant human growth hormone | rhGH | Somatotropin (human) | Somatotropin human | Somatotropin human growth hormone | Somatropin | Somatropin (rDNA origin) | Somatropin (recombinant DNA origin) | Somatropin [rDNA origin] | Somatropin recombinant | Somatropin(recombinant DNA origin) | Somatotropin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.